Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2019

01-03-2019 | Original Article

Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation

Authors: E. A. Aalbersberg, B. J. de Wit – van der Veen, M. W. J. Versleijen, L. J. Saveur, G. D. Valk, M. E. T. Tesselaar, M. P. M. Stokkel

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2019

Login to get access

Abstract

Introduction

Somatostatin receptor imaging with PET is the standard of care for patients with a neuroendocrine tumour (NET). Since therapy and imaging with somatostatin analogues utilize the same receptor, current guidelines recommend withdrawing long-acting somatostatin analogues for 3-4 weeks prior to somatostatin receptor PET imaging. The aim of this study is to prospectively assess the effect of lanreotide use on the uptake of 68Ga-DOTATATE intra-individually 1 day prior to and 1 day post injection of lanreotide.

Methods

Thirty-four patients with metastatic and/or unresectable NET and currently on lanreotide therapy for at least 4 months were included in the study. A 68Ga-DOTATATE PET/CT scan was performed on the day before and the day after lanreotide injection. In each patient 68Ga-DOTATATE uptake (SUVmax, mean, peak) was assessed in both tumour lesions and normal tissue. All scans were assessed by two blinded nuclear medicine physicians for visual analysis. Paired T-tests were performed to determine the differences between the scans.

Results

Of the 34 patients included, 31 were available for analyses in which 190 tumour lesions were measured. Uptake of 68Ga-DOTATATE in tumour lesions was increased significantly after lanreotide, but decreased significantly in the liver, spleen, and thyroid gland resulting in a higher tumour-to-liver ratio.

Conclusion

Lanreotide injection prior to 68Ga-DOTATATE PET/CT does not result in decreased tumour uptake. In contrast, tumour uptake was increased, whereas the uptake in normal organs is decreased, leading to an increased tumour-to-liver ratio. However, these differences were small and not deemed clinically relevant. These results strongly suggest that discontinuation of lanreotide injections in the weeks prior to 68Ga-DOTATATE PET examinations is unnecessary and does not compromise nuclear medicine imaging results.
Literature
1.
2.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;77030:1335–42.CrossRef
3.
Oberg K, Castellano D. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev. 2011;30(Suppl 1):3–7.CrossRefPubMed
4.
Cakir M, Dworakowska D, Grossman A. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2–clinical implications. J Cell Mol Med. 2010;14:2585–91.CrossRefPubMedPubMedCentral
5.
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27:4656–63.CrossRefPubMed
6.
Caplin ME, Pavel M, Cwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33.CrossRefPubMed
7.
Johnbeck CB, Knigge U, Kjaer A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10:2259–77.CrossRefPubMed
8.
Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013;40:1770–80.CrossRefPubMed
9.
Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester H-J, et al. Internalization of sst 2, sst 3, and sst 5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med. 2006;47:502–11.PubMed
10.
de Jong M, Breeman WAP, Bernard BF, van Gameren A, Schaar M, Bakker WH, et al. Tumor uptake of the radiolabeled somatostatin analog [DOTA- 0,Tyr-3] octreotide is dependent on the peptide amount. Eur J Nucl Med. 1999;26:693–8.CrossRefPubMed
11.
Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging. 2017;44:1588–601.CrossRefPubMed
12.
Haug AR, Rominger A, Mustafa M, Auernhammer C, Goke B, Schmidt GP, et al. Treatment with octreotide does not reduce tumor uptake of 68 Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med. 2011;52:1679–83.CrossRefPubMed
13.
Ayati N, Lee ST, Zakavi SR, Pathmaraj K, Qatawneh L, Poon A, et al. Long-acting somatostatin analog therapy differentially alters 68 Ga-DOTATATE uptake in normal tissues compared to primary tumors and metastatic lesions. J Nucl Med. 2017;59:223–7.CrossRefPubMed
14.
Janson E, Kalkner K, Eriksson B, Westlin J, Oberg K. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors. Nucl Med Biol. 1999;26:877–82.CrossRefPubMed
15.
Virgolini I, Ambrosini V, Bomanji JB, Fanti S, Gabriel M, Papathanasiou ND, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10.CrossRefPubMed
16.
Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sorensen J, Bergstrom M, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl Med Biol. 2010;37:265–75.CrossRefPubMed
17.
Dörr U, Wurm K, Höring E, Guzman G, Räth U, Bihl H. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs. Horm Metab Res Suppl. 1993;27:36–43.PubMed
18.
Dorr U, Rath U, Sautter-Bihl M, Guzman G, Bach D, Adrian H, et al. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med. 1993;20:431–3.CrossRefPubMed
19.
Sabet A, Nagarajah J, Dogan AS, Biersack H-J, Sabet A, Guhlke S, et al. Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors. EJNMMI Res. 2013;3:82–7.CrossRefPubMedPubMedCentral
20.
21.
Astruc B, Marbach P, Bouterfa H, Denot C, Safari M, Vitaliti A, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol. 2005;45:836–44.CrossRefPubMed
22.
Brogsitter C, Zöphel K, Hartmann H, Schottelius M, Wester H-J, Kotzerke J. Twins in spirit part II: DOTATATE and high-affinity DOTATATE – the clinical experience. Eur J Nucl Med Mol Imaging. 2014;41:1158–65.CrossRefPubMed
23.
Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, Baum RP. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC. Recent Results Cancer Res. 2013;194:519–36.CrossRefPubMed
24.
Puszkiel A, Bauriaud-Mallet M, Bourgeois R, Dierickx L, Courbon F, Chatelut E. Evaluation of the interaction of amino acid infusion on 177Lu-Dotatate pharmacokinetics in patients with gastroenteropancreatic neuroendocrine tumors. Clin Pharmacokinet. 2018.
Metadata
Title
Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation
Authors
E. A. Aalbersberg
B. J. de Wit – van der Veen
M. W. J. Versleijen
L. J. Saveur
G. D. Valk
M. E. T. Tesselaar
M. P. M. Stokkel
Publication date
01-03-2019
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2019
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-018-4117-x

Other articles of this Issue 3/2019

European Journal of Nuclear Medicine and Molecular Imaging 3/2019 Go to the issue

Original Article

Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience

Original Article

Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma

Original Article

Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study

Letter to the Editor

Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy

Image of the Month

Ectopic corticotropin-releasing hormone syndrome caused by pancreatic neuroendocrine tumor localized by 68Ga-DOTATATE PET/CT

Editorial

The evolving Editorial Board